CAR-T cell therapy: current limitations and potential strategies.
Sterner RC, Sterner RM. · 2021
Read CAR-T cell therapy: current limitations and potential strategies. by Sterner RC, Sterner RM. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8024391.txt.
Description
Sterner and Sterner review the limits of CAR-T cell therapy and the strategies meant to beat them. CAR-T cells are patient T cells re-engineered to hunt cancer. The approach produced striking results in some B cell leukemias and lymphomas. Anti-CD19 CAR-T therapy won FDA approval in 2017. Yet many barriers still cap its reach.
The pair list severe, life-threatening toxicities among the chief problems. Antigen escape lets tumors dodge the engineered cells. Trafficking into solid tumors is poor, and infiltration weaker still. The tumor microenvironment further blunts the cells. The review then covers fresh engineering ideas. These aim to raise anti-tumor power while cutting toxicity. Training a workforce for this complex therapy also gets attention.
Catalog record
| CREATOR | Sterner RC, Sterner RM. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |